SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
2018 · Acta Diabetologica · 247 citations
https://doi.org/10.1007/s00592-018-1116-0
R
Robert Puckrin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
61
Papers
646
Citations
10
h-index
13
i10-index
Robert Puckrin is an academic researcher from University of Calgary. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & CNS Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research. The author has an h-index of 10, co-authored 52 publications.
ORCID: 0000-0002-8918-6598Papers by this author
worksHigh-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
2023 · Journal of Clinical Oncology · 42 citations
https://doi.org/10.1200/jco.23.00365
Long‐term survivorship care after <scp>CAR‐T</scp> cell therapy
2023 · European Journal Of Haematology · 19 citations
https://doi.org/10.1111/ejh.14100
Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia
2024 · European Journal Of Haematology · 2 citations
https://doi.org/10.1111/ejh.14376
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Cancer Cell · 2 citations
https://doi.org/10.1016/j.ccell.2025.03.014
Impact of Underlying Disease and Total Body Irradiation on the Incidence of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
2025 · Transplantation and Cellular Therapy · 1 citations
https://doi.org/10.1016/j.jtct.2024.12.024
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat